Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

+ 252A/G polymorphism in lymphotoxin-α gene influences long-term survival in patients with myelodysplastic syndrome with excess blasts.

Xu J, Wang J, Ai X, Xu Z, Qin T, Fang L, Zhang H, Pan L, Hu N, Zhang Y, Xiao Z.

Leuk Lymphoma. 2014 Jun;55(6):1406-7. doi: 10.3109/10428194.2013.832242. Epub 2013 Sep 9. No abstract available.

PMID:
23931336
2.

Myelodysplastic syndrome: a review of 35 patients.

Bursztyn M, Douer D, Ramot B.

Isr J Med Sci. 1987 Nov;23(11):1140-4.

PMID:
3436796
3.

Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.

Kim M, Chung S, See CJ, Yoon SS, Kim BK, Kim HK, Lee DS.

Leuk Res. 2012 Feb;36(2):163-8. doi: 10.1016/j.leukres.2011.08.021. Epub 2011 Sep 13.

PMID:
21920602
4.

The +252A/G polymorphism in the Lymphotoxin-α gene and the risk of non-Hodgkin lymphoma: a meta-analysis.

Cao C, Liu S, Lou SF, Liu T.

Eur Rev Med Pharmacol Sci. 2014;18(4):544-52. Review.

5.

Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).

Geyer JT, Verma S, Mathew S, Wang YL, Racchumi J, Espinal-Witter R, Subramaniyam S, Knowles DM, Orazi A.

Hum Pathol. 2013 Mar;44(3):346-56. doi: 10.1016/j.humpath.2012.05.022. Epub 2012 Sep 17.

PMID:
22995330
6.

Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome.

Aktas D, Koc A, Boduroglu K, Hicsonmez G, Tuncbilek E.

Cancer Genet Cytogenet. 2000 Jan 1;116(1):44-6.

PMID:
10616531
7.

Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group.

Matsushima T, Murakami H, Sawamura M, Tamura J, Sakura T, Matsumoto M, Hirabayashi H, Miyawaki S, Simano S, Sato S, et al.

Br J Haematol. 1993 Aug;84(4):636-8.

PMID:
8217821
8.

Prognostic factors in the myelodysplastic syndromes.

Tricot GJ.

Leuk Res. 1992;16(1):109-15. Review.

PMID:
1732663
9.

Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome.

Goasguen JE, Bennett JM, Cox C, Hambley H, Mufti G, Flandrin G.

Leuk Res. 1991;15(12):1159-65.

PMID:
1766264
10.

No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes.

Mitani K, Hangaishi A, Imamura N, Miyagawa K, Ogawa S, Kanda Y, Yazaki Y, Hirai H.

Leukemia. 1997 Jun;11(6):863-5.

PMID:
9177441
11.

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY.

Haematologica. 2014 Jan;99(1):28-36. doi: 10.3324/haematol.2013.091249. Epub 2013 Aug 30.

12.

N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.

Paquette RL, Landaw EM, Pierre RV, Kahan J, Lübbert M, Lazcano O, Isaac G, McCormick F, Koeffler HP.

Blood. 1993 Jul 15;82(2):590-9.

13.

Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.

Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, Hirashima K, Hotta T, Kuramoto A, Kuriya S, et al.

Int J Hematol. 1993 Aug;58(1-2):53-61.

PMID:
8219112
14.
15.

Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.

Lundberg LG, Hellström-Lindberg E, Kanter-Lewensohn L, Lerner R, Palmblad J.

Leuk Res. 2006 Mar;30(3):247-53. Epub 2005 Aug 15.

PMID:
16099505
16.

[Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].

Kokhno AV, Parovichnikova EN, Mikhaĭlova EA, Ustinova EN, Kaplanskaia IB, Dvirnyk VN, Ol'shanskaia IuV, Domracheva EV, Savchenko VG.

Ter Arkh. 2010;82(8):48-53. Russian.

PMID:
20873246
17.

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC, Hayden J, Donaldson N, Aul C, Gattermann N, Giagounidis A, Germing U, List AF, Mufti GJ.

Blood. 2007 Nov 1;110(9):3365-73. Epub 2007 Jul 18.

18.

Apoptosis and prognostic factors in myelodysplastic syndromes.

Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M.

Leuk Lymphoma. 2002 Feb;43(2):257-60. Review.

PMID:
11999555
19.

Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.

Sakuma T, Hayashi Y, Kanomata N, Murayama T, Matsui T, Kajimoto K, Hanioka K, Chihara K, Maeda S.

Pathol Int. 2006 Apr;56(4):191-9.

PMID:
16634964
20.

[Myelodysplastic syndromes: current diagnosis and classification].

Tsvetaeva NV, Zavadenko MA, Ol'shanskaia IuV, Glasko EN, Khoroshko ND.

Ter Arkh. 2001;73(4):62-6. Russian. No abstract available.

PMID:
11494452

Supplemental Content

Support Center